A method of generating an oncogenic index of one or more patient specific mutations, comprising the steps of: a. forming an addressable array of a first set of expression constructs harboring genes comprising patient specific mutations, and a second set of expression constructs of corresponding wild type genes; b. adding an expression vector encoding for a Fluorescence Translocation Reporter gene comprising a target gene portion linked to a specific reporter gene portion for each locus in the addressable array; c. adding viable assay cells to each locus under conditions enabling transfection of the expression constructs and expression vectors into the assay cells; d. comparing the subcellular localization and/or translocation of the expressed FTR in the assay cells expressing the genes comprising the mutation with their corresponding wild type expressed genes to identify a disparate result; e. quantifying the disparate result of the candidate patient specific mutation, by: i) processing the disparate result to determine the degree of translocation of the tested FTR in the presence of the first set of expression constructs and the second set of expression construct to determine activation level of the patient specific mutations; ii) normalizing the degree of translocation of the FTR in the presence of the first set of expression vectors, based on the degree of translocation of the FTR in the presence of the second set of expression constructs, to determine normalized activation level of the patient specific mutations; and iii) analyzing the mapping between the normalized activation level of the patient specific mutations and a clinical outcome (reference); to thereby determine the oncogenic grading index of said one or more patient specific mutations. a. forming an addressable array of a first set of expression constructs harboring genes comprising patient specific mutations, and a second set of expression constructs of corresponding wild type genes; b. adding an expression vector encoding for a Fluorescence Translocation Reporter gene comprising a target gene portion linked to a specific reporter gene portion for each locus in the addressable array; c. adding viable assay cells to each locus under conditions enabling transfection of the expression constructs and expression vectors into the assay cells; d. comparing the subcellular localization and/or translocation of the expressed FTR in the assay cells expressing the genes comprising the mutation with their corresponding wild type expressed genes to identify a disparate result; e. quantifying the disparate result of the candidate patient specific mutation, by: i) processing the disparate result to determine the degree of translocation of the tested FTR in the presence of the first set of expression constructs and the second set of expression construct to determine activation level of the patient specific mutations; ii) normalizing the degree of translocation of the FTR in the presence of the first set of expression vectors, based on the degree of translocation of the FTR in the presence of the second set of expression constructs, to determine normalized activation level of the patient specific mutations; and iii) analyzing the mapping between the normalized activation level of the patient specific mutations and a clinical outcome (reference); i) processing the disparate result to determine the degree of translocation of the tested FTR in the presence of the first set of expression constructs and the second set of expression construct to determine activation level of the patient specific mutations; ii) normalizing the degree of translocation of the FTR in the presence of the first set of expression vectors, based on the degree of translocation of the FTR in the presence of the second set of expression constructs, to determine normalized activation level of the patient specific mutations; and iii) analyzing the mapping between the normalized activation level of the patient specific mutations and a clinical outcome (reference);